Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig™, 311C90)

@article{Rolan1997PotentialDI,
  title={Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig{\texttrademark}, 311C90)},
  author={Paul Edward Rolan},
  journal={Cephalalgia},
  year={1997},
  volume={17},
  pages={21 - 27}
}
  • P. Rolan
  • Published 1997
  • Medicine
  • Cephalalgia
Seven randomized studies in healthy volunteers have investigated interactions between zolmitriptan (Zomig™, formerly 311C90), a 5HT1B/1D agonist for acute migraine therapy, and selected drugs with which there was a possibility of interaction or a likelihood of concurrent use. Co-administration of oral dihydroergotamine, ergotamine, pizotifen, fluoxetine, paracetamol (acetaminophen)/metoclopramide or selegiline had no clinically significant effects on the pharmacokinetics of zolmitriptan or its… Expand
The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
TLDR
Moclobemide inhibited the metabolism of rizatriptan and its active N-monodesmethyl metabolite through inhibition of MAO-A, and may considerably potentiate riz atriptan action. Expand
Zolmitriptan (Zomig™, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: An overview of efficacy
TLDR
Zolmitriptan is a highly effective acute oral antimigraine therapy, with 2.5 mg providing the optimal balance between efficacy and tolerability. Expand
The clinical pharmacokinetics of zolmitriptan
TLDR
The pharmacokinetics of zolmitriptan are simple, predictable and appropriate to an acute oral treatment for migraine. Expand
Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.
TLDR
Moclobemide increased plasma concentrations of almotriptan on average by 37%, but the combined administration of these two compounds was well tolerated, and the degree of interaction was much less than that seen previously for sumatriptan or zolmitriptan given with moclobEMide. Expand
The Metabolism of Zolmitriptan
TLDR
Increased exposure to zolmitriptan and 183C91 by cimetidine indicated that a reduction in the total daily recommended dose of zolMITriptan may be necessary when treating migraine patients who are taking nonspecific cytochrome P450 inhibitors or specific cy tochrome 1A2 inhibitors. Expand
Tolerability Profile of Zolmitriptan (Zomig™; 311C90), a Novel Dual Central and Peripherally Acting 5HT1B/1D Agonist: International Clinical Experience Based on > 3000 Subjects Treated with Zolmitriptan
TLDR
Zolmitriptan is well tolerated, particularly at the recommended dose of 2.5 mg, and is well suited as an acute oral treatment for migraine in the outpatient setting, and has a well-defined dose-response, proving highly effective and optimizing the benefit/risk ratio of treatment. Expand
The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects
TLDR
Plasma concentrations of zolmitriptan were higher in Japanese females than males (AUC 40% and Cmax 29% higher), consistent with the results previously obtained in Caucasians. Expand
Pharmacokinetics and Pharmacodynamics of the Triptan Antimigraine Agents
TLDR
The pharmacological properties of the triptans (time to peak plasma concentration, half-life, bioavailability and receptor binding) are reviewed and related to efficacy and time of onset and the effects of concomitant medication, food, age and disease are considered. Expand
Migraine pharmacotherapy with oral triptans: a rational approach to clinical management
TLDR
Knowledge of the metabolic, pharmacokinetic and clinical profiles of the TELs facilitates the selection of a triptan which allows optimisation of the clinical benefits for individual patients, minimising the risk of drug interactions and a minimally effective dose to reduce potential adverse events (AEs). Expand
Indolealkylamines: Biotransformations and Potential Drug–Drug Interactions
  • A. Yu
  • Biology, Medicine
  • The AAPS Journal
  • 2008
TLDR
An important role for polymorphic cytochrome P450 2D6 (CYP2D 6) in the metabolism of IAA drugs of abuse has been revealed by recent studies, suggesting that variations in IAA metabolism, pharmaco- or toxicokinetics and dynamics can arise from distinct CYP2D6 status, and CYP1D6 polymorphism may represent an additional risk factor in the use of these IAAdrugs. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Lack of Interaction Between Pizotifen and the Novel Antimigraine Compound Zolmitriptan in Healthy Volunteers
TLDR
Zolmitriptan was well tolerated both alone and in combination with pizotifen, and there is no contraindication to the use of zolMITriptan nor a need for dosage modification in patients concomitantly receiving pizOTifen. Expand
The clinical pharmacokinetics of zolmitriptan
TLDR
The pharmacokinetics of zolmitriptan are simple, predictable and appropriate to an acute oral treatment for migraine. Expand
Tolerability Profile of Zolmitriptan (Zomig™; 311C90), a Novel Dual Central and Peripherally Acting 5HT1B/1D Agonist: International Clinical Experience Based on > 3000 Subjects Treated with Zolmitriptan
TLDR
Zolmitriptan is well tolerated, particularly at the recommended dose of 2.5 mg, and is well suited as an acute oral treatment for migraine in the outpatient setting, and has a well-defined dose-response, proving highly effective and optimizing the benefit/risk ratio of treatment. Expand
311C90: Increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists
TLDR
Clinical studies have shown 311C90 to be rapidly and consistently effective in relieving migraine headache, with initial doses of between 2.5 and 5 mg providing an optimal balance between efficacy and safety considerations. Expand
The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers.
TLDR
311C90 showed no clinically significant effects on blood pressure, heart rate, ECG or laboratory variables at any dose and demonstrated a tolerability and pharmacokinetic profile compatible with an acute oral migraine treatment. Expand
Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan.
TLDR
Zolmitriptan is well tolerated, particularly at the recommended dose of 2.5 mg, and is well suited as an acute oral treatment for migraine in the outpatient setting, despite pre-clinical and neurophysiological evidence of a dual peripheral and central action of zolMITriptan. Expand
Pre-clinical pharmacology of zolmitriptan (Zomig™; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine
  • G. Martin
  • Medicine
  • Cephalalgia : an international journal of headache
  • 1997
TLDR
A novel preclinical profile not only distinguishes zolmitriptan from sumatriptan, but raises intriguing questions about the clinical relevance of a dual action. Expand
Lack of Interaction Between Oral Dihydroergotamine and the Novel Antimigraine Compound Zolmitriptan in Healthy Volunteers
TLDR
It is suggested that zolmitriptan can be used in conjunction with oral dihydroergotamine without special precautions and there were no clinically significant changes in ECGs and adverse experiences were typical of 5HT1b/1d agonists. Expand
Peripheral Vascular Effects and Pharmacokinetics of the Antimigraine Compound, Zolmitriptan, in Combination with Oral Ergotamine in Healthy Volunteers
TLDR
Zolmitriptan, at eight times the likely therapeutic dose, was generally well tolerated both alone and in combination with ergotamine, which produced small degrees of peripheral vasoconstriction, including increases in diastolic blood pressure and blood flow velocity and decreases in arterial diameter and toe-arm systolic pressure gradient. Expand
Clinical Pharmacokinetics of Fluoxetine
TLDR
There appears to be a therapeutic window for fluoxetine, and the pharmacokinetics of this drug are not affected by either obesity or renal impairment, which makes this drug particularly suitable for use in elderly patients with depression. Expand
...
1
2
3
4
...